Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease.

International Journal of Molecular Sciences
Mohammad ArastooSoumya Palliyil

Abstract

Despite continued efforts, there remain no disease-modifying drugs approved by the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA) to combat the global epidemic of Alzheimer's disease. Currently approved medicines are unable to delay disease progression and are limited to symptomatic treatment. It is well established that the pathophysiology of this disease remains clinically silent for decades prior to symptomatic clinical decline. Identifying those at risk of disease progression could allow for effective treatment whilst the therapeutic window remains open for preservation of quality of life. This review aims to evaluate critically the current advances in the interpretation of tau-based biomarkers and their use to provide insights into the onset and progression of Alzheimer's disease, whilst highlighting important future directions for the field. This review emphasises the need for a more comprehensive analysis and interrogation of tau within biological fluids, to aid in obtaining a disease specific molecular signature for each stage of Alzheimer's disease. Success in achieving this could provide essential utility for presymptomatic patient selection for clinical trials, monitoring disease ...Continue Reading

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M GoedertR A Crowther
Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C M WischikR A Crowther
Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·I Grundke-IqbalL I Binder
Oct 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L KennerH Denk
Jan 1, 1996·European Archives of Psychiatry and Clinical Neuroscience·C BancherF Leblhuber
Sep 1, 1996·Journal of Neurochemistry·Y GuY Ihara
Nov 14, 2002·Neuromolecular Medicine·Dick TerwelFred Van Leuven
Jun 5, 2004·Dementia and Geriatric Cognitive Disorders·Harald Hampel, Stefan J Teipel
Nov 2, 2004·Journal of Neural Transmission·C-X GongK Iqbal
Oct 3, 2006·Brain : a Journal of Neurology·Katharina BuergerHarald Hampel
Dec 7, 2007·The European Journal of Neuroscience·Fei LiuCheng-Xin Gong
Aug 9, 2008·Journal of Alzheimer's Disease : JAD·Rudy J CastellaniMark A Smith
Apr 21, 2009·Neurobiology of Aging·Joseph L PriceJohn C Morris
Aug 4, 2009·International Journal of Geriatric Psychiatry·Kajsa SämgårdElisabet Londos
Feb 27, 2010·Annals of Neurology·John C MorrisMark A Mintun
Nov 4, 2010·Journal of Geriatric Psychiatry and Neurology·Lynn M BekrisDebby W Tsuang
Mar 11, 2011·Neurobiology of Aging·Amy M PoolerDiane P Hanger
Aug 16, 2011·Journal of Alzheimer's Disease : JAD·Min ShiJing Zhang
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Oct 11, 2012·Scientific Reports·Cristian A Lasagna-ReevesRakez Kayed
Mar 27, 2013·Progress in Neurobiology·Min Jae LeeDavid C Rubinsztein
Oct 12, 2013·PloS One·Jere E MeredithCharles F Albright
Jan 24, 2014·The New England Journal of Medicine·Stephen SallowayUNKNOWN Bapineuzumab 301 and 302 Clinical Trial Investigators

❮ Previous
Next ❯

Citations

Oct 23, 2021·The European Journal of Neuroscience·Xiao-Yu LiuPing Xu

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
transgenic
glycosylation
acetylation
ubiquitination
immunoprecipitation

Software Mentioned

SIMOA
AA
NIA

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.